Clinical trial NCT03527277: Orange Juice And Sugar Intervention Study
Official title: The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Risk Factor
Type2 Diabetes Mellitus
Insulin Sensitivity
Metabolic Syndrome
Keywords: orange juice
sugar-sweetened beverage
triglyceride
low density lipoprotein cholesterol
apolipoprotein B
uric acid
de novo lipogenesis
hepatic triglyceride
hepatic glucose production
whole body insulin sensitivity
Lead sponsor: University of California, Davis
Sponsor class: OTHER
Collaborators: name: Touro University, California
First posted: 2018-05-17
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized controlled trial
Primary purpose: BASIC_SCIENCE

Brief summary: The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.

Detailed description: Specific Aims: There is considerable epidemiological evidence that demonstrates associations between added sugar/sugar-sweetened beverage consumption and increased risk for or prevalence of chronic diseases such as cardiovascular disease (CVD), type 2 diabetes (T2D), metabolic syndrome, and gout. Especially concerning is recent evidence from National Health and Nutrition Examination Survey III that demonstrates that there is increased risk of CVD mortality with increased intake of added sugar across quintiles (Yang, 2014). Even the US mean added sugar intake, 15% of daily calories, was associated with an 18% increase in risk of CVD mortality over 15 years. The results from the investigator's recently completed study (1R01 HL09133) corroborate these findings (Stanhope, 2015). They demonstrate that supplementing the ad libitum diets of young adults with beverages containing 0, 10, 17.5 or 25% of daily energy requirement (Ereq) as high fructose corn syrup (HFCS) affects lipid/lipoprotein risk factors for CVD in a dose response manner. Specifically, levels of nonHDL-cholesterol(C), LDL-C, apolipoprotein B (apoB), and postprandial triglycerides (TG) increased linearly over a 2-week period with increasing doses of HFCS. Furthermore, even the participants consuming the 10% Ereq dose exhibited increased levels of these risk factors compared to baseline.

These and similar results have helped to lead to reductions in soda consumption in this country, and new dietary guidelines and FDA food labeling requirements to promote reductions in added sugar consumption. However, there are gaps in knowledge about other sugar-containing foods that lead to public confusion concerning healthier options for soda, and impede further progress in implementing public health policies that will promote further reductions in soda consumption. One such food is naturally-sweetened fruit juice. The amount of sugar in fruit juice is comparable to the amount in soda. Because of this, a consumer seeking answers on the internet will find many articles in which experts state or suggest that the effects of consuming fruit juice are as detrimental as or even worse than those of soda. However, in contrast to soda, fruit juice contains micronutrients and bioactives that may promote health. Therefore the consumer can also find numerous articles on the internet where the health benefits of fruit juice and these bioactives are extolled. There are a limited number of clinical dietary intervention studies that have directly compared the metabolic effects of consuming fruit juice and sugar-sweetened beverage, and their results are not conclusive. Thus we will pursue the following Specific Aims:

1. Specific Aim 1: To compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages for 4 weeks on risk factors for CVD and other chronic disease in normal weight and overweight men and women.
2. Specific Aim 2: To mechanistically compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages on metabolic processes associated with the development of CVD and T2D in normal weight and overweight men and women.
3. Specific Aim 3: To relate the changes assessed under Specific Aims 1 and 2 to the changes in the urinary levels of metabolites and catabolites of the main flavanones in orange juice, hesperetin and naringenin.

Eligibility criteria: Inclusion Criteria: men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight \> than 50 kg Self-reported stable body weight during the prior six months

Exclusion Criteria:

Fasting glucose \>125 mg/dl Evidence of liver disorder (AST or ALT \>200% upper limit of normal range) Evidence of kidney disorder (\>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides \> 400 mg/dl LDL-C \> 160 mg/dl in combination with Chol:HDL \> 4 Hemoglobin \< 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.

Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (\>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.

Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk

-

Primary outcomes:
measure: Low density lipoprotein cholesterol (LDL-C)
timeFrame: 4 weeks
measure: Apolipoprotein B (apoB)
timeFrame: 4 weeks
measure: Uric acid
timeFrame: 4 weeks
measure: de novo lipogenesis (DNL)
timeFrame: 4 weeks
measure: Hepatic triglyceride
timeFrame: 4 weeks
measure: Endogenous glucose production
timeFrame: 4 weeks
Secondary outcomes:
measure: Postprandial triglyceride
timeFrame: 4 weeks
measure: 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic
timeFrame: 4 weeks
measure: hesperetin-3'-O-glucuronide
timeFrame: 4 weeks
measure: hesperetin-3'-sulfate
timeFrame: 4 weeks
measure: Apolipoprotein CIII (apoCIII)
timeFrame: 4 weeks
measure: non-high density lipoprotein cholesterol (non-HDL-C)
timeFrame: 4 weeks
Other outcomes:
measure: Gluconeogenesis
timeFrame: 4 weeks
measure: Glycogenolysis
timeFrame: 4 weeks
measure: Lipolysis
timeFrame: 4 weeks
measure: Triglyceride production
timeFrame: 4 weeks
measure: Energy expenditure
timeFrame: 4 weeks
measure: Fat oxidation
timeFrame: 4 weeks
measure: Hesperetin-7-O-glucuronide
timeFrame: 4 weeks
measure: Naringenin-4'-O-glucuronide
timeFrame: 4 weeks
measure: Naringen-7-O-glucuronide
timeFrame: 4 weeks
measure: Fecal microbiota
timeFrame: 4 weeks
measure: Insulin
timeFrame: 4 week
measure: glucose
timeFrame: glucose
measure: Apolipoprotein E (apoE)
timeFrame: 4 weeks
measure: high sensitivity C reactive protein (CRP)
timeFrame: 4 weeks
measure: aspartate aminotransferase (AST)
timeFrame: 4 weeks
measure: alanine aminotransferase (ALT)
timeFrame: 4 weeks
measure: gamma-glutamyl transferase (GGT)
timeFrame: 4 weeks
measure: oxidized LDL (oxLDL)
timeFrame: 4 weeks
measure: malondialdehyde
timeFrame: 4 weeks
measure: total antioxidant status
timeFrame: 4 weeks
measure: soluble vascular cellular adhesion molecule (sVCAM-1)
timeFrame: 4 weeks
measure: monocyte chemotactic protein-1 (MCP-1)
timeFrame: 4 weeks
measure: nitric oxide metabolite (NOx)
timeFrame: 4 weeks
measure: Diastolic and systolic blood pressure
timeFrame: 4 weeks
measure: Body fat
timeFrame: 4 weeks
measure: Visceral fat
timeFrame: 4 weeks
measure: Subcutaneous fat
timeFrame: 4 weeks
measure: Physical activity
timeFrame: 4 weeks
measure: Eating motivation
timeFrame: 4 weeks
Locations:
city: Davis
country: United States
facility: University of California, Davis
state: California
Study officials:
affiliation: University of California, Davis
name: Kimber L Stanhope, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. 2014 Apr;174(4):516-24. doi: 10.1001/jamainternmed.2013.13563.
citation: Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL, Havel PJ. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015 Jun;101(6):1144-54. doi: 10.3945/ajcn.114.100461. Epub 2015 Apr 22.